NCT05762471View on ClinicalTrials.gov

Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

January 9, 2023

Primary Completion Date

April 11, 2024

Study Completion Date

April 11, 2024

Conditions
Overweight or ObesityType2 Diabetes Mellitus
Interventions
DRUG

GSBR-1290

Patients will receive GSBR-1290 or matching Placebo

DRUG

Placebo

Patients will receive GSBR-1290 or matching Placebo

Trial Locations (4)

32127

Progressive Medical Research, Port Orange

33143

QPS Miami Research Associates, Miami

91911

ProSciento, Inc, Chula Vista

92801

Anaheim Clinical Trials, Anaheim

All Listed Sponsors
lead

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

INDUSTRY